Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Open Access
- 1 September 2015
- journal article
- clinical trial
- Published by International Union Against Tuberculosis and Lung Disease in The International Journal of Tuberculosis and Lung Disease
- Vol. 19 (9), 1039-44, i
- https://doi.org/10.5588/ijtld.14.0829
Abstract
SETTING: Nine months of daily isoniazid (9H) and 3 months of once-weekly rifapentine plus isoniazid (3HP) are recommended treatments for latent tuberculous infection (LTBI). The risk profile for 3HP and the contribution of hepatitis C virus (HCV) infection to hepatotoxicity are unclear. OBJECTIVES: To evaluate the hepatotoxicity risk associated with 3HP compared to 9H, and factors associated with hepatotoxicity. DESIGN: Hepatotoxicity was defined as aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN) with symptoms (nausea, vomiting, jaundice, or fatigue), or AST >5 x ULN. We analyzed risk factors among adults who took at least 1 dose of their assigned treatment. A nested case-control study assessed the role of HCV. RESULTS: Of 6862 participants, 77 (1.1%) developed hepatotoxicity; 52 (0.8%) were symptomatic; 1.8% (61/3317) were on 9H and 0.4% (15/3545) were on 3HP (P CONCLUSION: The risk of hepatotoxicity during LTBI treatment with 3HP was lower than the risk with 9H. HCV and elevated baseline AST were risk factors for hepatotoxicity. For persons with these risk factors, 3HP may be preferred.Keywords
This publication has 15 references indexed in Scilit:
- New Regimens to Prevent Tuberculosis in Adults with HIV InfectionNew England Journal of Medicine, 2011
- The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection.2009
- An Official ATS Statement: Hepatotoxicity of Antituberculosis TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2006
- The Scope and Impact of Treatment of Latent Tuberculosis Infection in the United States and CanadaAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Isoniazid Preventive Therapy, Hepatitis C Virus Infection, and Hepatotoxicity among Injection Drug Users Infected withMycobacterium tuberculosisClinical Infectious Diseases, 2001
- Targeted Tuberculin Testing and Treatment of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Hepatotoxicity Associated With Isoniazid Preventive TherapyJAMA, 1999
- Isoniazid-associated Hepatitis Deaths: A Review of Available InformationAmerican Review of Respiratory Disease, 1992
- Detecting alcoholism. The CAGE questionnaireJAMA, 1984
- ISONIAZID-RELATED HEPATITIS - UNITED-STATES PUBLIC-HEALTH SERVICE COOPERATIVE SURVEILLANCE STUDYPublished by Elsevier BV ,1978